Core Insights - MSD (Merck & Co) reported strong Q4 2025 results with global sales of $16.4 billion, a 5% increase from Q4 2024, but has cut its 2026 sales guidance more than analysts expected due to impending loss of exclusivity for several drugs [1][2] - The company anticipates 2026 global sales between $65.5 billion and $67 billion, which is below the average analyst estimate of $67.6 billion [2] - Keytruda (pembrolizumab) was the top-performing drug with $31.7 billion in global sales, significantly contributing to the company's 2025 performance, but it will face loss of exclusivity later this decade [3] Financial Performance - Full-year sales for 2025 reached $65 billion, reflecting a 1% growth [1] - Q4 sales of Winrevair, a new drug for pulmonary arterial hypertension, were $467 million, marking a 133% increase from the previous year [5] Strategic Moves - The company is focusing on its pipeline and M&A activity to replace lost revenue, having completed a $10 billion acquisition of Verona Pharma and a $9.2 billion acquisition of Cidara Therapeutics in 2025 [4] - MSD is reportedly considering a potential acquisition of Revolution Medicines for up to $32 billion, although talks ended due to price disagreements [4] Future Outlook - CEO Rob Davis expressed confidence in sustainable growth post-loss of exclusivity, highlighting early-stage pipeline assets expected to be revealed in the next two years [5]